Length of stay and charges associated with health care-acquired bloodstream infections

Faculty of Nursing, AL AL-Bayt University, Mafraq, Jordan.
American journal of infection control (Impact Factor: 2.33). 05/2011; 40(3):227-32. DOI: 10.1016/j.ajic.2011.03.014
Source: PubMed

ABSTRACT Although many studies have examined outcomes of health care-associated bloodstream infections (HCABSIs), population-based estimates of length of stay (LOS) and costs have seldom been reported.
Our objective was to generate US national estimates of LOS and costs associated with HCABSIs using the 2003 National Inpatient Sample (NIS).
This study utilized a matched case-control design to estimate LOS and costs associated with HCABSIs based on the 2003 (NIS). A special set of ICD-9-CM codes was used to identify cases. A 1:1 matching procedure was used in which HCABSIs in patients were matched with uninfected patients based on age, sex, and admission diagnosis. We performed weighted analysis to construct population estimates and their standard deviations for LOS and total charges.
After applying the case finding criteria, 113,436 HCABSI cases were identified. The weighted mean LOS for HCABSIs cases was 16.0 days compared with 5.4 days for the control group (P < .001). The weighted mean total charges for patients with HCABSIs were $85,813 ($110,183 US in 2010) compared with $22,821 ($29,302 US in 2010) for uninfected patients (P < .001). We estimated that, in 2003, HCABSIs potentially cost the US economy nearly $29 billion ($37.24 billion US in 2010).
This study estimated the economic burden of HCABSIs on the US national economy. With some modifications, the annually published NIS data could be useful as a national surveillance tool for health care adverse events including HCABSIs.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Streptococcal bacteremia occurs during hematopoietic cell transplantation (HCT), and treatment of active oral disease may reduce this risk. The objective of this study was to determine the type, number, and costs of pre-transplantation dental procedures in this population. Data were collected retrospectively from the records of patients who were to undergo HCT. The type, number, and costs of dental procedures were determined based on median charges of MassHealth (the Medicaid program in Massachusetts) and also on the median "usual and customary" fees charged by dentists in Massachusetts. A total of 405 patients were evaluated. There were 243 men (60%) and 162 women, with a median age of 53 years. The median and average costs (in US dollars) of dental treatment before HCT were $275 and $384, respectively, for patients covered by MassHealth and $368 and $522, respectively, for those with private insurance, adjusted to 2012 levels. Dental evaluation before HCT is an economical way for patients to minimize the risk of localized infection and possibly reduce the risk of bacteremia that may prolong the length of hospitalization.
    01/2014; 117(1):59-66. DOI:10.1016/j.oooo.2013.08.021
  • [Show abstract] [Hide abstract]
    ABSTRACT: Central line-associated bloodstream infections (CLABSI) are common types of hospital-acquired infections associated with high morbidity. Little is known about the attributable cost and length of stay (LOS) of CLABSI in pediatric inpatient settings. We determined the cost and LOS attributable to pediatric CLABSI from 2008 through 2011. A propensity score-matched case-control study was performed. Children <18 years with inpatient discharges in the Nationwide Inpatient Sample databases from the Healthcare Cost and Utilization Project from 2008 to 2011 were included. Discharges with CLABSI were matched to those without CLABSI by age, year, and high dimensional propensity score (obtained from a logistic regression of CLABSI status on patient characteristics and the presence or absence of 262 individual clinical classification software diagnoses). Our main outcome measures were estimated costs obtained from cost-to-charge ratios and LOS for pediatric discharges. The mean attributable cost and LOS between matched CLABSI cases (1339) and non-CLABSI controls (2678) was $55 646 (2011 dollars) and 19 days, respectively. Between 2008 and 2011, the rate of pediatric CLABSI declined from 1.08 to 0.60 per 1000 (P < .001). Estimates of mean costs of treating patients with CLABSI declined from $111 852 to $98 621 (11.8%; P < .001) over this period, but cost of treating matched non-CLABSI patients remained constant at ∼$48 000. Despite significant improvement in rates, CLABSI remains a burden on patients, families, and payers. Continued attention to CLABSI-prevention initiatives and lower-cost CLABSI care management strategies to support high-value pediatric care delivery is warranted.
    PEDIATRICS 05/2014; 133(6). DOI:10.1542/peds.2013-3795 · 5.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We compared the aetiology of 203 ICU--acquired laboratory confirmed bloodstream infections (LC--BSI) prospectively collected between January 2000--December 2007 (first period) with 83 LC--BSI recorded between January 2010--December 2012 (second period), after the diffusion in 2008 of K. pneumoniae expressing carbapenem--resistance due to K. pneumoniae carbapenemases production (KPC--CR--Kp). In the general ICU of teaching hospital "Umberto I" in Rome, all ICU--acquired LC--BSI episodes occurring in patients admitted to ICU ≥48h were included. Baseline characteristics, clinical features, antimicrobial resistance and outcome were recorded. All isolated strains multidrug resistance (MDR) were evaluated according to the European Centre for Disease Control (ECDC) guidelines. Overall the study included 329 isolates, 214 in 2000--2007 and 115 in 2010--2012. In the second period we registered a Gram--positive reduction (55.1% vs. 26.9%; p<0.01) and Gram--negative increase (40.2% vs. 69.6%; p<0.01). In 2000--2007 staphylococci were responsible for 45.8% LC--BSI's, whereas 18.3% during 2010--2012. Enterobacteriaceae increased dramatically (15.4% vs. 39.2%; p<0.01), especially Klebsiella spp. (5.6% vs. 31.3%; p<0.01). LC--BSI associated mortality decreased among Gram--positive (56.8% vs. 51.6%), but increased in Gram--negative (41.9% vs. 60.0%; p<0.03), especially in Enterobacteriaceae (RR 2.13; 95%CI 1.21 - 3.73; p<0.01). MDR increased remarkably among Enterobacetriaceae (51.5% vs. 73.3%). The study highlighted the associated mortality for Enterobacteriaceae when comparing MDR to non--MDR microorganisms. ICU--acquired LC--BSI aetiology shifted from Gram--positive to Gram--negative during the study period in our ICU. Also associated mortality decreased among the former, whereas it increased in the latter. Last MDR increased enormously among Enterobacteriaceae with the diffusion of KPC (75% of strains), adding significantly to associated mortality (RR 2.17; 1.16 - 4.05; p<0.01).
    Minerva anestesiologica 11/2014; · 2.27 Impact Factor

Full-text (3 Sources)

Available from
Dec 17, 2014